Cochrane · systematic review · CD008125
Sulpiride augmentation for schizophrenia
Wang, J, Omori, IM, Fenton, M, et al. · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 6 · 85.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG compared to ANY ANTIPSYCHOTIC DRUG for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: No clinically important response ‐ short term SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG | RR 0.58 [0.3, 1.09] | 3 studies · 193 participants | Low Downgraded: risk of bias |
Specific adverse effects: 1a. CNS ‐ short term ‐ movement disorder ‐ extrapyramidal effects SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG | RR 48.24 [3.05, 762.56] | 1 study · 70 participants | Very low Downgraded: risk of bias |
Specific adverse effects: 3a. Endocrine system ‐ short term ‐ weight gain SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG | RR 0.3 [0.09, 0.99] | 1 study · 64 participants | Low Downgraded: risk of bias |
Specific adverse effects: 4. Gastrointestinal system ‐ short term ‐ salavation ‐ too much SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG | RR 0.49 [0.29, 0.83] | 3 studies · 162 participants | Low Downgraded: risk of bias |
Mental state: 1a. General ‐ No clinical important improvement ‐ BPRS ‐ short term SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG | RR 0.55 [0.32, 0.92] | 1 study · 28 participants | Low Downgraded: risk of bias |
Mental state: 2a. Negative symptoms ‐ No clinical important improvement ‐ negative symptoms (SANS) SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG | RR 0.76 [0.56, 1.04] | 1 study · 28 participants | Low Downgraded: risk of bias |
SENSITIVITY ‐ Global/mental state: No clinically important response ‐ short term SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG | RR 0.56 [0.36, 0.88] | 4 studies · 221 participants | Low Downgraded: risk of bias |